查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600441

制酸剂市场：依药物类别、剂型、适应症、通路划分 - 全球预测 2025-2030

Antacids Market by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Formulation (Liquid, Powder, Tablet), Indication, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年制酸剂市值为68.5亿美元，预计到2024年将达到72.4亿美元，复合年增长率为5.81%，到2030年将达到101.8亿美元。

制酸剂市场包括各种非处方药和处方药，旨在中和胃酸并缓解与胃酸倒流、消化不良和胃灼热相关的症状。由于不健康的饮食、压力和久坐的生活方式等生活方式因素引起胃肠道疾病的广泛流行，因此需要制酸剂。制酸剂的应用主要在医疗保健和製药业，针对需要立即缓解消化器官系统不适的消费者。制酸剂被多种人群使用，包括老年人、孕妇和患有慢性胃肠道问题的人。市场成长的推动因素包括胃肠道健康意识的提高、自我治疗趋势的增加以及咀嚼片和调味片的日益普及，这些片剂吸引了更广泛的人群。

主要市场统计
基准年[2023] 68.5亿美元
预测年份 [2024] 72.4亿美元
预测年份 [2030] 101.8亿美元
复合年增长率（%） 5.81%

主要影响因素是全球胃肠道疾病增加导致消化器官系统健康市场快速成长。潜在的成长机会存在于中产阶级人口不断增长和医疗保健意识增强的新兴市场。公司应投资创新产品配方，以满足注重健康的消费者的需求，例如砂糖、纯素和有机产品。然而，监管障碍、长期使用的潜在副作用以及质子帮浦阻断剂和 H2 受体拮抗剂等替代疗法的竞争等挑战可能会阻碍市场成长。此外，错误讯息和缺乏正确使用意识可能会导致消费者困惑。

为了克服这些限制，需要进行研究和开发来延长鬆弛时间、最大限度地减少副作用并提高患者的依从性。增强的递送机制，例如速效液体製剂和可溶性条带，也可以提高竞争力。关于抗酸化合物和肠道微生物群相互作用的高级研究为个人化胃肠道护理提供了尚未开发的潜力。制酸剂市场是动态的、由消费者主导的，需要不断创新和策略行销来应对不断变化的消费者需求和偏好，同时克服监管和竞争挑战。

市场动态：揭示快速发展的制酸剂市场的关键市场洞察

供需的动态交互作用正在改变制酸剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 胃食道逆流病人口增加
    • 全球政府对国内药品製造的措施与投资
  • 市场限制因素
    • 针对酸相关问题的家庭疗法和其他替代方法的可用性
  • 市场机会
    • 开发效果更立竿见影、效果更持久的制酸剂
    • 在线药房可以轻鬆获得制酸剂，并且成药的监管灵活性
  • 市场挑战
    • 与制酸剂相关的药品召回和污染问题

波特的五力：驾驭制酸剂市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解制酸剂市场的外部影响

外部宏观环境因素在塑造制酸剂市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解制酸剂市场的竞争状况

制酸剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵制酸剂市场供应商绩效评估

FPNV定位矩阵是评估制酸剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分了供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 患有胃食道逆流的人数正在增加
      • 全球政府对国内药品製造的措施与投资
    • 抑制因素
      • 针对酸度相关问题的家庭疗法和其他替代疗法的可用性
    • 机会
      • 开发具有更直接和持久效果的制酸剂
      • 线上药局可以轻鬆可得性制酸剂，并且成药的监管灵活性
    • 任务
      • 与制酸剂相关的药品召回和污染问题
  • 市场区隔分析
    • 药物类别：酸中和剂越来越受欢迎以提高治疗效果
    • 适应症：在胃食道逆流症的治疗中越来越需要制酸剂，以减少胃酸对食道内壁的损害。
    • 配方：人们越来越喜欢液体制酸剂，因为它们在溶解状态下可以更快地缓解症状。
    • 通路：零售药局制酸剂的供应量增加，无需处方笺即可轻鬆取得制酸剂
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的制酸剂市场

  • 酸中和剂
    • 氢氧化铝
    • 碳酸钙
    • 氢氧化镁
    • 碳酸氢钠
  • H2拮抗剂
  • 促销代理
  • 质子帮浦抑制剂

第七章 处方制酸剂市场

  • 液体
  • 粉末
  • 锭剂

第八章按适应症分類的制酸剂市场

  • 胃食道逆流症
  • 消化不良/消化不良
  • 消化性溃疡

第九章制酸剂市场：按通路

  • 医院药房
  • 网路药房
  • 零售药房

第十章美洲制酸剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太制酸剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲/中东/非洲制酸剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • TUMS 与 DraftKings 和 Desus Nice 合作推出TUMS Prop Bites，让大型游戏迷第一次可以尽情享受美食。
    • Dexel Pharma 收购八个 OTC 品牌以强化消费者保健产品组合
    • Camber Pharmaceuticals 推出非专利Wellbutrin SR
    • 利洁时在泰米尔纳德邦推出 Gaviscon Double Action，帮助患有胃酸过多和胃灼热的人们
    • Wonderberry 扩展到 1,800 多家 Target 商店，以便更轻鬆地接触更广泛的客户群
    • 剪切机-Smith 推出法莫替丁口服悬浮液
    • ZydusEsomeprazole唑镁产品获得美国FDA 最终核准
    • Wonder Berry制酸剂为目标族群提供独特口味
    • Mark Sands Pharma 法莫替丁锭获得美国FDA核准
    • ENO 推出两种新口味扩大产品组合：Jaljeera 和 Nimbu Masala

公司名单

  • Abbott Laboratories
  • Aero Healthcare AU Pty Ltd
  • Alcon Industries
  • Alkem Laboratories Ltd.
  • Allegiant Health
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Camber Pharmaceuticals, Inc.
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Dexcel Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline PLC
  • Haleon PLC
  • Imerys SA
  • JB Chemicals & Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Magmit Pharmaceutical Co., Ltd.
  • Mankind Pharma Ltd.
  • Marksans Pharma
  • Nestle SA
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Raritan Pharmaceuticals, Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Swiss Chem Healthcare by Swastik Lifesciences
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals
  • Wonderbelly
  • Zoic Pharmaceuticals Pvt. Ltd.
Product Code: MRR-4358BACA7E3E

The Antacids Market was valued at USD 6.85 billion in 2023, expected to reach USD 7.24 billion in 2024, and is projected to grow at a CAGR of 5.81%, to USD 10.18 billion by 2030.

The antacids market encompasses a wide range of over-the-counter and prescription medications intended to neutralize stomach acidity and alleviate symptoms associated with acid reflux, indigestion, and heartburn. The necessity of antacids stems from the widespread prevalence of gastrointestinal diseases caused by lifestyle factors such as unhealthy diets, stress, and sedentary habits. Their application is primarily within the healthcare and pharmaceutical industries, targeting consumers in need of immediate relief from digestive discomfort. Antacids are used by a diverse demographic, including older adults, pregnant women, and individuals with chronic gastrointestinal issues. The market's growth is fueled by rising awareness of gastrointestinal health, increased self-medication trends, and the rising popularity of chewable tablets and flavored versions that appeal to a broader audience.

KEY MARKET STATISTICS
Base Year [2023] USD 6.85 billion
Estimated Year [2024] USD 7.24 billion
Forecast Year [2030] USD 10.18 billion
CAGR (%) 5.81%

A key influencing factor is the burgeoning digestive health market, driven by the increase in gastrointestinal diseases globally. Potential growth opportunities reside in emerging markets with a rising middle-class population and increasing healthcare awareness. Companies should invest in innovative product formulations like sugar-free, vegan-friendly, and organic antacids that cater to health-conscious consumers. However, challenges such as regulatory hurdles, the potential side effects of long-term use, and competition from alternative treatments like proton pump inhibitors and H2-receptor antagonists may hinder market growth. Furthermore, misinformation and a lack of awareness regarding appropriate usage can lead consumers astray.

To overcome these limitations, research can be directed towards developing antacids with extended relief duration, minimal side effects, and improved patient compliance. Enhanced delivery mechanisms like fast-acting liquid formulations or dissolvable strips could also provide a competitive edge. Advanced studies on gut microbiota interactions with antacid compounds offer untapped potential for personalized digestive care. The antacids market is dynamic and consumer-driven, requiring continuous innovation and strategic marketing to cater to varying consumer needs and preferences while navigating the challenges posed by regulation and competition.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antacids Market

The Antacids Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing population suffering from gastroesophageal reflux disease
    • Government initiatives and investments for domestic drug manufacturing worldwide
  • Market Restraints
    • Availability of home remedies and other alternatives for acidity-related issues
  • Market Opportunities
    • Development of more instantly effective and long-lasting antacids
    • Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
  • Market Challenges
    • Drug recall and contamination issues associated with the antacids

Porter's Five Forces: A Strategic Tool for Navigating the Antacids Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antacids Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antacids Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antacids Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antacids Market

A detailed market share analysis in the Antacids Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antacids Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antacids Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aero Healthcare AU Pty Ltd, Alcon Industries, Alkem Laboratories Ltd., Allegiant Health, AstraZeneca plc, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals, Inc., Cipla Limited, Daiichi Sankyo Company Limited, Dexcel Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Imerys S.A., J. B. Chemicals & Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Magmit Pharmaceutical Co., Ltd., Mankind Pharma Ltd., Marksans Pharma, Nestle S.A., Novartis AG, Perrigo Company plc, Pfizer Inc., Raritan Pharmaceuticals, Inc., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Swiss Chem Healthcare by Swastik Lifesciences, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals, Wonderbelly, and Zoic Pharmaceuticals Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Antacids Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Acid Neutralizers, H2 Antagonist, Promotility Agents, and Proton Pump Inhibitor. The Acid Neutralizers is further studied across Aluminum Hydroxide, Calcium Carbonate, Magnesium Hydroxide, and Sodium Bicarbonate.
  • Based on Formulation, market is studied across Liquid, Powder, and Tablet.
  • Based on Indication, market is studied across Gastroesophageal Reflux Disease, Indigestion/Dyspepsia, and Peptic Ulcer Disease.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing population suffering from gastroesophageal reflux disease
      • 5.1.1.2. Government initiatives and investments for domestic drug manufacturing worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of home remedies and other alternatives for acidity-related issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of more instantly effective and long-lasting antacids
      • 5.1.3.2. Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Drug recall and contamination issues associated with the antacids
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for acid neutralizers for improved therapeutic action
    • 5.2.2. Indication: Expanding need for antacids for the management of gastroesophageal reflux disease for reducing the acid's ability to damage the esophageal lining.
    • 5.2.3. Formulation: Rising preference for liquid antacid due to their already dissolved state, facilitating quicker relief from symptoms
    • 5.2.4. Distribution Channel: Growing availability of antacids across retail pharmacies that provide instant access to antacids without the need for a prescription
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antacids Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Acid Neutralizers
    • 6.2.1. Aluminum Hydroxide
    • 6.2.2. Calcium Carbonate
    • 6.2.3. Magnesium Hydroxide
    • 6.2.4. Sodium Bicarbonate
  • 6.3. H2 Antagonist
  • 6.4. Promotility Agents
  • 6.5. Proton Pump Inhibitor

7. Antacids Market, by Formulation

  • 7.1. Introduction
  • 7.2. Liquid
  • 7.3. Powder
  • 7.4. Tablet

8. Antacids Market, by Indication

  • 8.1. Introduction
  • 8.2. Gastroesophageal Reflux Disease
  • 8.3. Indigestion/Dyspepsia
  • 8.4. Peptic Ulcer Disease

9. Antacids Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Antacids Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antacids Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antacids Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
    • 13.3.2. Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
    • 13.3.3. Camber Pharmaceuticals Launches Generic Wellbutrin SR
    • 13.3.4. Reckitt Launches Gaviscon Double Action in Tamil Nadu, Helping People with Acidity and Heartburn
    • 13.3.5. Wonderbelly Expands To Over 1,800 Target Stores to be Easily Accessible to a Broader Audience
    • 13.3.6. Upsher-Smith Launches Famotidine For Oral Suspension
    • 13.3.7. Zydus Secures Final Approval from the USFDA for its Esomeprazole Magnesium Product
    • 13.3.8. Wonderbelly Antacid Brings Exclusive Flavor to Target With Launch
    • 13.3.9. Marksans Pharma Gets USFDA Nod for Famotidine Tablets
    • 13.3.10. ENO Expands its Portfolio with Two New Flavors, Jaljeera and Nimbu Masala

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aero Healthcare AU Pty Ltd
  • 3. Alcon Industries
  • 4. Alkem Laboratories Ltd.
  • 5. Allegiant Health
  • 6. AstraZeneca plc
  • 7. Bayer AG
  • 8. Biocon Limited
  • 9. Boehringer Ingelheim International GmbH
  • 10. Cadila Pharmaceuticals Limited
  • 11. Camber Pharmaceuticals, Inc.
  • 12. Cipla Limited
  • 13. Daiichi Sankyo Company Limited
  • 14. Dexcel Ltd.
  • 15. Dr. Reddy's Laboratories Ltd.
  • 16. GlaxoSmithKline PLC
  • 17. Haleon PLC
  • 18. Imerys S.A.
  • 19. J. B. Chemicals & Pharmaceuticals Limited
  • 20. Johnson & Johnson Services, Inc.
  • 21. Magmit Pharmaceutical Co., Ltd.
  • 22. Mankind Pharma Ltd.
  • 23. Marksans Pharma
  • 24. Nestle S.A.
  • 25. Novartis AG
  • 26. Perrigo Company plc
  • 27. Pfizer Inc.
  • 28. Raritan Pharmaceuticals, Inc.
  • 29. Reckitt Benckiser Group PLC
  • 30. Sanofi S.A.
  • 31. Sun Pharmaceutical Industries Ltd.
  • 32. Swiss Chem Healthcare by Swastik Lifesciences
  • 33. Takeda Pharmaceutical Company Limited
  • 34. Teva Pharmaceutical Industries Ltd.
  • 35. The Procter & Gamble Company
  • 36. Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals
  • 37. Wonderbelly
  • 38. Zoic Pharmaceuticals Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTACIDS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTACIDS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTACIDS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTACIDS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTACIDS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTACIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTACIDS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTACIDS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTACIDS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTACIDS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTACIDS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTACIDS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTACIDS MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTACIDS MARKET SIZE, BY PROMOTILITY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTACIDS MARKET SIZE, BY PROTON PUMP INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTACIDS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTACIDS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTACIDS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTACIDS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTACIDS MARKET SIZE, BY INDIGESTION/DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTACIDS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTACIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTACIDS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTACIDS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. ANTACIDS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ANTACIDS MARKET, FPNV POSITIONING MATRIX, 2023